GANYMED Pharmaceuticals AG is a leading biopharmaceutical company offering smart antibody therapeutics for ideal targets in solid cancers.

GANYMED's discovery engine is one of the most powerful integrated solutions to building an antibody cancer pipeline in the industry. This is because GANYMED has brought together the strongest and most dynamic scientific team for translational medicine.

With a world leading expertise in pinpointing highly specific proprietary targets, GANYMED is building a growing sustainable pipeline of antibody therapeutics targeting solid cancers with high medical need and large market potential.

A multicenter first-in-man clinical Phase I study with GANYMED’s Claudiximab (iMAB362) antibody in patients with metastatic adenocarcinoma of the stomach and the lower esophagus has been successfully concluded in the second quarter of 2010 up to a dose of 1g/sqm, without observing any serious related adverse events.

GANYMED has five further antibody projects in non-clinical development in solid cancers with high unmet medical need, including melanomas, prostate cancers, lung cancers, breast cancers, colorectal cancers, and head & neck cancers.

Founded in 2001 as a spin-off from the Universities of Mainz and Zurich, the Company is located in Mainz, Germany and has 70 employees.